Health and social care bursary scheme opens
Insurance Corporation, which runs the scheme, said it aimed to recognise the dedication of health and social care workers in Guernsey.
It said the project deemed most beneficial to the Bailiwick community would be awarded £3,000, with £1,500 for a runner-up.
The bursary champions a wide variety of projects tackling topics such as alcohol abuse, bereavement, elderly falls, eating disorders, mental health, diabetes, memory care, and midwifery, it said.
Mark Marshall, managing director of Insurance Corporation, said: "For 34 years, we've been astounded by the quality and diversity of the projects submitted.
"The knowledge and talent within HSC are incredible, and it's inspiring to see such innovative ideas from frontline workers."
Michelle Steele, HR and PR executive, said: "We are incredibly proud of our long-standing contribution to the local community.
"Each year we're impressed by the creativity and compassion that really shines through.
"It's amazing to see these projects come to life and make a real difference in the Bailiwick - and in some cases, even further afield."
More news stories for Guernsey
Listen to the latest news for Guernsey
Follow BBC Guernsey on X and Facebook and Instagram. Send your story ideas to channel.islands@bbc.co.uk.
Regulator ups fees due to 'mismanaged' insurers
Further delays to Guernsey's patient record system
Insurance Corporation - 2025 Health & Social Care Bursary
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Man took diet advice from ChatGPT, ended up hospitalized with hallucinations
A man was hospitalized for weeks and suffered from hallucinations after poisoning himself based on dietary advice from ChatGPT. A case study published on Aug. 5 in the Annals of Internal Medicine, an academic journal, states the 60-year-old man decided he wanted to eliminate salt from his diet completely. To do so, he asked ChatGPT for an alternative to salt, or sodium chloride, to which the AI chatbot suggested sodium bromide, a compound historically used in pharmaceuticals and manufacturing. While the journal noted that doctors were unable to review the original AI chat logs and that the bot likely suggested the substitution for another purpose, such as cleaning, the man purchased sodium bromide and used it in place of table salt for three months. As a result, he ended up in the ER with paranoid delusions, despite having no history of mental health problems. Convinced that his neighbor was poisoning him, the man was reluctant to even accept water from the hospital, despite reporting extreme thirst. He continued to experience increased paranoia, as well as auditory and visual hallucinations, eventually landing him an involuntary psychiatric hold after he tried to escape during treatment. What was happening to the man? Doctors determined that the man was suffering from bromide toxicity (or bromism), which can result in neurological and psychiatric symptoms, as well as others experienced by the man, including acne and cherry angiomas (bumps on the skin), fatigue, insomnia, subtle ataxia (clumsiness) and polydipsia (excessive thirst). Other symptoms of bromism can include nausea and vomiting, diarrhea, tremors or seizures, drowsiness, headache, weakness, weight loss, kidney damage, respiratory failure and coma, according to iCliniq. Bromism was once far more common due to bromide salts having been used in everyday products. In the early 20th Century, it was used in over-the-counter medications, often resulting in neuropsychiatric and dermatological symptoms, according to the study's authors. Incidents of such poisoning saw a sharp decline when the Food and Drug Administration phased out the use of bromides in pharmaceuticals between the mid 70s and late 1980s. The man was treated at the hospital for three weeks, over which time his symptoms progressively improved. USA TODAY reached out to OpenAI, the maker of ChatGPT, for comment on Wednesday, Aug. 13, but has not received a response. The company provided Fox News Digital with a statement, saying, "Our terms say that ChatGPT is not intended for use in the treatment of any health condition, and is not a substitute for professional advice. We have safety teams working on reducing risks and have trained our AI systems to encourage people to seek professional guidance." AI can 'fuel the spread of misinformation,' doctors say Doctors involved in the case study said they suspected that the patient had used ChatGPT version 3.5 or 4.0, the former of which they tested in an attempt to replicate the answers the man received. While the study's authors noted that they couldn't know exactly what the man was told without the original chat log, they did receive a suggestion for bromide as a replacement for chloride in their tests. "Though the reply stated that context matters, it did not provide a specific health warning, nor did it inquire about why we wanted to know, as we presume a medical professional would do," said study authors Dr. Audrey Eichenberger, Dr. Stephen Thielke and Dr. Adam Van Buskirk. AI carries the risk of providing information like this without context, according to the doctors. For example, it is unlikely that a medical expert would have mentioned sodium bromide at all if a patient asked for a salt substitute. "Thus, it is important to consider that ChatGPT and other AI systems can generate scientific inaccuracies, lack the ability to critically discuss results, and ultimately fuel the spread of misinformation," according to the study. This article originally appeared on USA TODAY: Man hospitalized after taking ChatGPT diet advice, study says Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Provident Healthcare Partners Advises OrthoNY on its Partnership with Zenyth Partners
BOSTON and NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised OrthoNY in a recapitalization with Zenyth Partners ("Zenyth") to form Evolve Orthopedic Partners ("Evolve"). OrthoNY is a leading orthopedic care provider in the Capital Region of New York with 43 physicians and 84 total providers, dedicated to providing high quality musculoskeletal care to patients across its eight clinics and three ambulatory surgery centers. Provident's deal team was led by Managing Directors Eric Major and Scott Davis. McGuireWoods LLP served as legal counsel to ONY, and Alston & Bird LLP served as legal counsel to Zenyth. "Provident brought the clarity, confidence and expertise we needed to navigate this complex process. From day one, they took the time to understand our goals, challenge our thinking and keep us focused on the bigger picture," said David Fitzgerald, CEO of OrthoNY. "Their commitment never wavered, from early calls to late-night check-ins, they were true partners every step of the way. We're grateful to have had their guidance," added Dr. Lee Kaback, Vice President of OrthoNY. "They understood what makes OrthoNY unique and helped us protect and strengthen that as we look toward the future." "The OrthoNY leadership team engaged with Provident under the vision of developing a new regionally focused musculoskeletal platform with a partner. Zenyth Partners is a perfect match given their dedicated thesis in the MSK sector and experience developing other provider platforms in the Northeast region. We look forward to following the continued success of Evolve," noted Major. About OrthoNYOrthoNY is a leading orthopedic practice providing comprehensive musculoskeletal care, including surgical and non-surgical treatments, across multiple locations in Upstate New York. The Company is recognized for its expertise in joint replacement, sports medicine, spine care, pain management and more. With a strong reputation for clinical excellence and compassionate care, OrthoNY continues to be a top choice for orthopedic services in the region. For more information, visit About Zenyth PartnersZenyth Partners is an operationally focused investment firm focused exclusively on building leading healthcare companies. Zenyth partners with entrepreneurs, clinicians, and operators that share similar values, creating differentiated healthcare organizations that support patients, providers, payors, and the community at large. For more information, visit About Provident Healthcare PartnersProvident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including orthopedics. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit or follow Provident on LinkedIn. Contact: Provident Healthcare PartnersEric Major 617-226-4212 emajor@ View original content to download multimedia: SOURCE Provident Healthcare Partners LLC
Yahoo
2 hours ago
- Yahoo
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
BOULDER, CO / / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for infants and children into large retailers in the United States. The antimicrobial hydrogel is being marketed and sold through Sonoma's U.S.-based distribution partner. The diaper rash product is currently carried in 3,600 Walmart stores, and certain large grocery chains. "We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma. "We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire
